Harmony Biosciences Holdings, Inc.: stock overview

HRMYNASDAQHealthcare · Pharmaceutical Preparations

Price

$33.76

November 13, 2026Market cap $2.0B

DCF calculator

What Ploutos Investor adds for Harmony Biosciences

Part of Ploutos Investor, €9.99 a month

See the plans
  • The full history: 7 fiscal years, from 2019
  • The estimated fair value, with its range and its certainty
  • The full analysis, 18 a month
  • More questions to the chat on its filings
  • Excel with every year
  • An email when it reports, changes its dividend or an officer buys

Sign in with a free account to see the last 5 fiscal years.

In short

Harmony Biosciences had revenue of $989M over the last 12 months and net income of $179M, a net margin of 18.1%. Revenue grew by 40.3% a year on average over the last 5 years. At $33.76 the shares trade at a P/E of 10.9, against a median of 15.2 over the last 5 fiscal years. It holds more cash than debt, by $622M. It pays no dividend.

From its SEC filings (latest fiscal year to December 31, 2025) and the price of November 13, 2026.

Its SEC filings
Market cap
$2.0B
57.84M shares
P/E
10.9
Today10.9
Median15.2
Revenue, 12 months
$989M
+40.3% a year over 5 years
Net margin
18.1%
2025: 18.3%, above 87% of its industry

Worth knowing

What a holder would want to hear from the company's SEC filings of the last three years. Each with its filing, without comment.

3 fiscal years in figures

Each fiscal year's figures as the company filed them, and the share price at its end.

2023–2025 fiscal years

+22.2% a year over 2 years

  • 202510-K
    Revenue$868M
  • 202410-K
    Revenue$715M
  • 202310-K
    Revenue$582M

Fiscal years in figures

HRMY's revenue, profit, cash flow and dividend with each year-end price, from 2019 to 2022, 4 more fiscal years

Part of Ploutos Investor, €9.99 a month

See the plans

Sign in with a free account to see the last 5 fiscal years.

Key figures

The company's current figures in five groups. Each term is explained behind its ⓘ.

Valuation

Market cap 3-year median: $2.0B
$2.0B
Enterprise value 
$1.3B
P/E 3-year median: 13.8
10.9
EV / EBIT 
6.1
EV / Revenue 
1.3
P/B 3-year median: 3.0
1.8
FCF yield 3-year median: 11.9%
16.5%
Earnings yield 3-year median: 7.2%
9.2%

Profitability

Gross margin 
74.0%
Operating margin 
22.2%
Net margin 3-year median: 20.4%
18.1%
ROIC 
15.3%
ROIC, 5-year average 
18.2%
ROE 
19.1%

Growth

Revenue, yearly change 
+21.5%
EPS, yearly change 
+8.0%
FCF, yearly change 
+59.1%
Revenue, average a year 
+40.3%

The yearly change compares FY2025 with FY2024.

Balance sheet

Cash 
$771M
Total debt 
$155M
Of which operating leases 
$5.8M
Net cash 
$622M
Net debt / EBITDA 
–
Interest cover 
17.0x
Current ratio 
3.44

Balance sheet of September 30, 2026.

Returns to shareholders

Dividend yield 
0.00%
Buybacks 
–
Total returned 
0.00%
Shares, yearly change 
+0.9%
Valuation against its own pastEach fiscal year's P/E, P/FCF and P/B beside today's, and the DCF calculator for the company.Valuation

Against its industry

Where its margins and returns stood in fiscal 2025 among the SEC filers of its industry (SIC code 28).

Gross margin

77.2%

Above 91% of the 141 companies in its industry, and 93% of all.

Operating margin

24.0%

Above 88% of the 285 companies in its industry, and 88% of all.

Net margin

18.3%

Above 87% of the 302 companies in its industry, and 80% of all.

ROE

18.2%

Above 79% of the 267 companies in its industry, and 81% of all.

ROA

12.5%

Above 84% of the 313 companies in its industry, and 91% of all.

Revenue growth

21.5%

Above 74% of the 292 companies in its industry, and 82% of all.

From the yearly figures every company files with the SEC, for those with revenue of at least $25 million. The industry is the first two digits of the SIC code.

The company at the SEC

How it is registered and when its fiscal year ends.

Name at the SEC
Harmony Biosciences Holdings, Inc.
CIK
1802665
Exchange
NASDAQ
Industry (SIC)
2834 · Pharmaceutical Preparations
Fiscal year ends
December 31
Latest annual report
December 31, 2025
Reporting currency
USD
Shares
57.84M

Other companies: Healthcare

The largest companies of the same sector, each with its own page.

The Healthcare sectorAll companies

The full analysis

What do Harmony Biosciences's filings show?

These are Harmony Biosciences's figures. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.

  • A fair value range built from the filings
  • Earnings quality, debt and red flags
  • Insider and institutional moves
  • The case for and the case against

Questions about HRMY

Didn't find what you were looking for?

Ask us
What is HRMY's market cap?

Harmony Biosciences Holdings, Inc.'s market cap is $2.0B, at a price of $33.76 on November 13, 2026 and 57.84M shares.

What is HRMY's P/E?

HRMY's P/E is 10.9, on earnings per share of $3.03 over the last 12 months. The median over the last 5 fiscal years was 15.2.

How much revenue does HRMY have?

Harmony Biosciences had revenue of $989M over the last 12 months. Over the last 5 years it changed by +40.3% a year on average.

Does HRMY pay a dividend?

No. Harmony Biosciences paid no regular dividend over the last 12 months.

Where do the figures come from?

From Harmony Biosciences Holdings, Inc.'s SEC filings (10-K and 10-Q) and the share price. They hold no analyst estimates and no score, and they are not a recommendation.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

US stocksThe market today, the sectors, the largest companies and the week's results.The market's sectorsThe 11 sectors side by side: returns, share of the market, median P/E and dividend.Compare stocksTwo companies side by side: price over up to ten years, with and without dividends, and every figure.US dividend stocksEach dividend's yield next to whether the company's cash covers it and whether it was ever cut.

The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.